Millions of dollars and countless hours spent building public trust could be undone if Health Canada finalizes its proposed new regulatory guidance for products of gene editing (also called genome editing). Despite biotechnology industry complaints that regulation is just red tape that hampers competitiveness, companies rely on the legitimacy that government regulation provides. If the […] Read more
Stories by Lucy Sharratt
GM, not Bill C-474, a risk to industry – Opinion
Lucy Sharratt, co-ordinator for the Canadian Biotechnology Action Network, provides another view on GM bill proposal. Bill C-474 is not, as Rick White of the Canadian Canola Growers Association argued in this space March 18, a “significant threat to the future competitiveness of our industry.” The issue here is not the future of canola but […] Read more
Stacked traits lack assessment – Opinion
Sharratt is the co-ordinator of the Canadian Biotechnology Action Network based in Ottawa. Monsanto and Dow AgroSciences are calling their new SmartStax corn a “game-changing” technology. How so? Is it the increased prices they will eventually charge for a corn with eight genetically engineered traits? Is it the 75 percent reduction in refuge area that […] Read more
